Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice

Lipids

Volumn 38, Issue 5, 2003, Pages 519-523

  Egawa, Tetsu ^a   Toda, Katsumi ^a   Nemoto, Yoshihisa ^a   Ono, Masafumi ^a   Akisawa, Naoaki ^a   Saibara, Toshiji ^a   Hayashi, Yoshihiro ^a   Hiroi, Makoto ^a   Enzan, Hideaki ^a   Onishi, Saburo ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDATION; RNA; TUMORS;

ESTROGENS;

LIPIDS;

ACYL COENZYME A DEHYDROGENASE; AROMATASE; ESTROGEN; LONG CHAIN FATTY ACID COENZYME A LIGASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PITAVASTATIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME DEFICIENCY; ESTROGEN SYNTHESIS; FATTY ACID OXIDATION; FATTY LIVER; FEMALE; GENE EXPRESSION; HYPERLIPIDEMIA; LIVER MICROSOME; LIVER MITOCHONDRION; MALE; NONHUMAN; NORTHERN BLOTTING; OBESITY; PEROXISOME; SIGNAL TRANSDUCTION; UNITED STATES;

ACYL-COA DEHYDROGENASE; ACYL-COA DEHYDROGENASE, LONG-CHAIN; ACYL-COA OXIDASE; ANIMALS; APOLIPOPROTEINS A; AROMATASE; BLOTTING, NORTHERN; CATALASE; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FATTY ACIDS; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; QUINOLINES; RNA, MESSENGER; TRIGLYCERIDES;

ANIMALIA;

EID: 10744219760     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-003-1093-x     Document Type: Article

References (28)

1. Kelly, D.P., Hale, D.E., Rutledge, S.L., Ogden, M.L., Whelan, A.J., and Strauss, A.W. (1989) The Tissue-Specific Expression and Developmental Regulation of Two Nuclear Genes Encoding Rat Mitochondrial Proteins: Medium-Chain Acyl-CoA Dehydrogenase and Mitochondrial Malate Dehydrogenase, J. Biol. Chem. 264, 18921-18925.
2. Nagao, M., Parimoo, B., and Tanaka, K. (1993) Developmental, Nutritional, and Hormonal Regulation of Tissue-Specific Expression of the Genes Encoding Various Acyl-CoA Dehydrogenase and α-Subunit of Electron Transfer Flavoprotein in Rat, J. Biol. Chem. 268, 24114-24124.
3. Disch, D.L., Rader, T.A., Cresci, S., Leone, T.C., Barger, P.M., Vega, R., Wood, P.A., and Kelly, D.P. (1996) Transcriptional Control of a Nuclear Gene Encoding a Mitochondrial Fatty Acid Oxidation Enzyme in Transgenic Mice: A Role for Nuclear Receptors in Cardiac and Brown Adipose Expression, Mol. Cell. Biol. 16, 4043-4051.
4. Nemoto, Y., Toda, K., Ono, M., Adachi, K.F., Saibara, T., Onishi, S., Enzan, H., Okada, T., and Shizuta, Y. (2000) Altered Constitutive Expression of Fatty Acid-Metabolizing Enzymes in Aromatase-Deficient (ArKO) Mice, J. Clin. Invest. 105, 1819-1825.
5. Saibara, T., Onishi, S., Ogawa, Y., Yoshida, S., and Enzan, H. (1999) Bezafibrate for Tamoxifen-Induced Non-Alcoholic Steatohepatitis, Lancet 353, 1802.
6. Gail, M.H., Costantino, J.P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., and Vogel, V. (1999) Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer, J. Natl. Cancer Inst. 91, 1829-1846.
7. Oien, K.A., Moffat, D., Curry, G.W., Dickson, J., Habeshaw, T., Mills, P.R., and MacSween, R.N.M. (1999) Cirrhosis with Steatohepatitis After Adjuvant Tamoxifen, Lancet 353, 36-37.
8. Pratt, D.S., Knox, T.A., and Erban, J. (1995) Tamoxifen-Induced Steatohepatitis, Ann. Intern. Med. 123, 236.
9. Pinto, H.C., Baptista, A., Camilo, M.E., de Costa, E.B., Valente, A., and de Moura, M.C. (1995) Tamoxifen-Associated Steatohepatitis - Report of Three Cases, J. Hepatol. 23, 95-97.
10. Van Hoof, M., Rahier, J., and Horsmans, Y. (1996) Tamoxifen-Induced Steatohepatitis, Ann. Intern. Med. 124, 855-856.
11. Ogawa, Y., Murata, Y., Nishioka, A., Inomata, T., and Yoshida, S. (1998) Tamoxifen-Induced Fatty Liver in Breast Cancer Patients, Lancet 351, 725.
12. Ludwig, J., Viggiano, T.R., McGill, D.B., and Ott, B. (1980) Nonalcoholic Steatohepatitis: Mayo Clinic Experiences with a Hitherto Unnamed Disease, Mayo Clin. Proc. 55, 434-438.
13. Falck-Ytter, Y., Younossi, Z.M., Marchesini, G., and McCullough, A.J. (2001) Clinical Features and Natural History of Nonalcoholic Steatosis Syndrome, Semin. Liver Dis. 21, 17-26.
14. Younossi, Z.M., Diehl, A.M., and Ong, J.P. (2002) Nonalcoholic Fatty Liver Disease: An Agenda for Clinical Research, Hepatology 35, 746-752.
15. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for Early Breast Cancer: An Overview of the Randomized Trials, Lancet 351, 1451-1467.
16. Yoshikawa, T., Toda, K., Nemoto, Y., Ono, M., Iwasaki, S., Maeda, T., Saibara, T., Hayashi, Y., Miyazaki, E., Hiroi, M., et al. (2002) Aromatase-Deficient (ArKO) Mice Are Retrieved from Severe Hepatic Steatosis by Peroxisome Proliferator Administration, Hepatol. Res. 22, 278-287.
17. Bolego, C., Baetta, R., Bellosta, S., Corsini, A., and Paoletti, R. (2002) Safety Considerations for Statins, Curr. Opin. Lipidol. 13, 637-644.
18. Martin, G., Duez, H., Blanquart, C., Berezowski, V., Poulain, P., Fruchart, J.C., Najib-Fruchart, J., Glineur, C., and Staels, B. (2001) Statin-Induced Inhibition of the Rho-Signaling Pathway Activates PPARα and Induces HDL apoA-I, J. Clin. Invest. 107, 1423-1432.
19. Aoki, T., Yoshinaka, Y., Yamazaki, H., Suzuki, H., Tamaki, T., Sato, F., Kitahara, M., and Saito, Y. (2002) Triglyceride-Lowering Effect of Pitavastatin [corrected] in a Rat Model of Post-prandial Lipemia, Eur. J. Pharmacol. 444, 107-113.
20. Noji, Y., Higashikata, T., Inazu, A., Nohara, A., Ueda, K., Miyamoto, S., Kajinami, K., Takegoshi, T., Koizumi, J., and Mabuchi, H. (2002) Long-Term Treatment with Pitavastatin (NK-104), a New HMG-CoA Reductase Inhibitor, of Patients with Heterozygous Familial Hypercholesterolemia, Atherosclerosis 163, 157-164.
21. Toda, K., Okada, K., Nakamura, K., Nishihara, M., Yokotani, K., and Shizuta, Y. (2000) Concentrations of Monoamines and Acetylcholine in the Brains of Mice Lacking the Aromatase Cytochrome P450 Gene, in Molecular Steroidgenesis, Okamoto, M., Ishimura, Y., and Newada, H., eds., Frontiers Science Series No. 29, pp. 141-143, University Academic Press, Tokyo.
22. Shindo, Y., Osumi, T., and Hashimoto, T. (1978) Effects of Administration of di-(2-Ethylhexyl) Phthalate on Rat Liver Mitochondria, Biochem. Pharmacol. 27, 2683-2688.
23. Yeldandi, A.V., Rao, M.S., and Reddy, J.K. (2000) Hydrogen Peroxide Generation in Peroxisome Proliferator-Induced Oncogenesis, Mutat. Res. 448, 159-177.
24. Gotto, A.M., Jr. (1997) Cholesterol Management in Theory and Practice, Circulation 96, 4424-4430.
25. West of Scotland Coronary Prevention Study Group, Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlene, P.W., McKillop, J.H., and Packard, C.J. (1995) Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia, New Engl. J. Med. 333, 1301-1307.
26. Vamecq, J., and Latruffe, N. (1999) Medical Significance of Peroxisome Proliferator-Activated Receptors, Lancet 354, 141-148.
27. Djouadi, F., Weinheiner, C.J., Saffitz, J.E., Pitchford, C., Bastin, J., Gonzalez, F.J., and Kelly, D.P. (1998) A Gender-Related Defect in Lipid Metabolism and Glucose Homeostasis in Peroxisome Proliferator-Activated Receptor α-Deficient Mice, J. Clin. Invest. 102, 1083-1091.
28. Wanless, I.R., and Lentz, J.S. (1990) Fatty Liver Hepatitis (steatohepatitis) and Obesity: An Autopsy Study with Analysis of Risk Factors, Hepatology 12, 1106-1110.